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Abstract
Background: Dengue virus infection causes a wide spectrum of illness, ranging from sub-clinical to severe disease. Severe
dengue is associated with sequential viral infections. A strict definition of primary versus secondary dengue infections
requires a combination of several tests performed at different stages of the disease, which is not practical.
Methods and Findings: We developed a simple method to classify dengue infections as primary or secondary based on the
levels of dengue-specific IgG. A group of 109 dengue infection patients were classified as having primary or secondary
dengue infection on the basis of a strict combination of results from assays of antigen-specific IgM and IgG, isolation of virus
and detection of the viral genome by PCR tests performed on multiple samples, collected from each patient over a period of
30 days. The dengue-specific IgG levels of all samples from 59 of the patients were analyzed by linear discriminant analysis
(LDA), and one- and two-dimensional classifiers were designed. The one-dimensional classifier was estimated by bolstered
resubstitution error estimation to have 75.1% sensitivity and 92.5% specificity. The two-dimensional classifier was designed
by taking also into consideration the number of days after the onset of symptoms, with an estimated sensitivity and
specificity of 91.64% and 92.46%. The performance of the two-dimensional classifier was validated using an independent
test set of standard samples from the remaining 50 patients. The classifications of the independent set of samples
determined by the two-dimensional classifiers were further validated by comparing with two other dengue classification
methods: hemagglutination inhibition (HI) assay and an in-house anti-dengue IgG-capture ELISA method. The decisions
made with the two-dimensional classifier were in 100% accordance with the HI assay and 96% with the in-house ELISA.
Conclusions: Once acute dengue infection has been determined, a 2-D classifier based on common dengue virus IgG kits
can reliably distinguish primary and secondary dengue infections. Software for calculation and validation of the 2-D classifier
is made available for download.
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Introduction
Dengue virus (DENV) is a member of the family Flaviviridae,
genus Flavivirus, with four antigenically distinct serotypes (DENV-1
to DENV-4). Infection with this virus is a growing public health
concern in tropical and subtropical regions of the world, with an
estimated incidence of 50–100 million cases per year [1]. Dengue
virus infection in humans causes a large spectrum of illness ranging
from mild sub-clinical disease to a severe and occasionally fatal
hemorrhagic clinical form, the dengue hemorrhagic fever (DHF)
[2]. Severe complications of dengue infections such as DHF are
mainly associated with sequential infection [3,4]. The lack of
adequate tools to predict whether a patient infected with dengue
virus will progress with the benign form or with life-threatening
disease has often resulted in a large number of unnecessary and
costly hospitalizations, which during dengue outbreaks have led to
a public health crisis by creating a shortage of hospital beds [5].
Consequently, the differentiation of primary from secondary
infection may be of great prognostic value for dengue patients,
particularly children and the elderly, in whom a secondary dengue
infection is more likely to result in DHF [4,5]. Also, for
epidemiological purposes, it is important to characterize the
dengue serological immune response during dengue outbreaks [5].
There is no doubt that clinical observation is the most important
criterion for dengue diagnosis; nevertheless, definitive diagnosis of
the disease requires laboratory confirmation [6,7,8]. ELISA-based
detection of specific antibodies (both IgM and IgG) to the four
dengue serotypes is valuable for the diagnosis of acute infection
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and for detection of previous exposure to dengue virus [8,9]. The
hemagglutination inhibition (HI) test [10], based on antibody
titering of paired serum specimens and recommended by the
World Health Organization (WHO) [7], is the method that has
most frequently been used for serologic classification of dengue
infections. However, this assay is time-consuming and cross-
reactions among Flavivirus have been noted [6]. The plaque
reduction neutralizing test (PRNT) [11] may be also used, but this
assay is difficult for most laboratories to perform, and the fact that
the results take several days to obtain tends to limit its clinical
usefulness.
Thus, an accurate, timely and affordable assay that could be
used to characterize the serologic response to DENV infection is
clearly desirable. As an alternative to the HI test, several
laboratories have developed and evaluated ELISA-format tests
to detect IgG antibodies [12,13]. The IgG ELISA has the
advantage of being easier to perform, as well as being suitable for
surveillance and large-scale studies [14]. A number of commercial
and standardized ELISA kits for both IgM and IgG antibody
detection have also become available. The commercial IgG-
capture ELISA kits that have been evaluated have shown good
correlation with the HI assay [15]. However, the ability of both in-
house ELISAs and commercial kits to classify accurately primary
and secondary dengue infections still needs to be validated with
standard reference samples.
This report shows how to design a linear 2-dimensional (2-D)
classifier to assign primary and secondary dengue infection status
to patients based on their IgG response, as measured by assays of
samples taken on different days after onset of symptoms. This
study is based on a set of IgG antibody data for patients from a
well-characterized dengue cohort in the city of Recife, Brazil [16],
where a commercial dengue IgG-ELISA kit is routinely used. In
this kit the IgG-based classification of dengue infection is based on
the use of a constant cut-off value to discriminate between the two
types of infection, regardless of disease stage (as measured here by
the number of days from the onset of symptoms). In the present
study, we describe how to develop a reliable 2-D classifier that
takes into account the disease stage and the IgG antibody level,
and we demonstrate that this approach shows excellent perfor-
mance with independent test data obtained from patients with
independently verified primary or secondary dengue infections.
Materials and Methods
Study population and specimen collection
Volunteers were recruited among subjects with more than five
years of age who were admitted to one of three hospitals in the city
of Recife —Instituto Materno Infantil de Pernambuco (IMIP),
Hospital Esperanc¸a (HE) and Hospital Santa Joana (HSJ) —
under suspicion of an acute dengue infection. Disease day 1 was
the day of onset of symptoms, as reported by the patient. Blood
samples were collected at the time of the first visit to the hospital.
The patients had from two to five blood samples taken, on various
days after the onset of disease. All first serum samples were
evaluated using the standard tests: virus isolation, RT-PCR and
serology (IgM and IgG). Serology only was carried out on all
subsequent samples. Highly-experienced technicians performed all
the assays in a blinded fashion, before any assignment of primary
or secondary infection was made. Dengue cases were laboratory-
confirmed by virus isolation and/or viral RNA detection by RT-
PCR and/or by a positive anti-dengue, IgM-capture ELISA. A
subset of samples collected during the two first years of the cohort
(2004–2005) was employed. The complete clinical-epidemiological
description of the cohort is described elsewhere [16]. The
demographic description of the subjects in this study is presented
in Table 1.
Reference Standard (‘‘Recife’’ method)
During the 2004–2005 period, the cohort had 230 subjects
enlisted with confirmed dengue cases. From those 230 cases, 109
where unambiguously classified as primary or secondary infections
based on a series of multiple standard methods (see below), and a
total of 322 blood samples were obtained from these subjects. All
the reference samples were strictly assigned by the authors
according to the following criteria: 1) Primary infection (P) was
characterized by absence of dengue specific IgG antibodies in the
acute serum sample and presence of anti-dengue IgM, virus
isolation and/or viral RNA detection, followed by the presence of
anti-dengue IgG in convalescent serum samples; 2) Secondary
infection (S) was characterized by presence of specific anti-dengue
IgG in the acute sample and absence of anti-dengue IgM,
associated with a positive RT-PCR and/or virus isolation;
followed by the presence of anti-dengue IgM in convalescent
serum samples. All unambiguously assigned samples were included
in this study; no exclusions were made. The remaining 111 dengue
cases could not be rigorously defined as primary or secondary
dengue infections based on the criteria above and did not
participate in the development of the classifier.
Ethical considerations
Written consent to participate in the study was obtained from
each patient (or the patient’s guardian) after a full explanation of
the study was provided. All data were handled confidentially and
anonymously. This study was reviewed and approved by the ethics
committee of the Brazilian Ministry of Health (Nu 4909 CONEP)
and The Johns Hopkins University School of Medicine internal
review board (# 03-08-27-01).
Cohort serum collection
Blood samples were collected into 10 ml VacutainerH tubes
(Becton Dickinson, Franklin Lakes, NJ). Serum was separated by
centrifuging the tubes at 1,6006g for 10 min. Samples (1 ml per
tube) were stored in two cryovials at 280uC and 220uC for later
use in virus isolation, RT-PCR and serology.
Virus isolation and identification
For DENV isolation, serum samples were inoculated onto a
monolayer of C6/36 cells [17]. Cells were harvested after 10–14
Table 1. Demographic of the patients. Primary and
Secondary infection Information is based on the CPqAM
classification criteria.
SUBJECT AGE Years GENDER TYPE OF INFECTION
Male Female Total Primary Secondary
5–9 1 1 1
10–14 1 3 4 2 2
15–24 9 8 17 14 3
25–34 13 16 29 15 14
35–44 17 11 28 16 12
$45 14 16 30 10 20
TOTAL 54 55 109 57 52
doi:10.1371/journal.pone.0004945.t001
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days of incubation, and checked for the presence of virus by
immunofluorescence assay. The dengue virus was identified with
serotype-specific monoclonal antibodies as described by Gubler et al.
[18].
Reverse transcriptase- polymerase chain reaction (RT-PCR)
Viral RNA was extracted from serum samples using a QIAquick
PCR Purification kit (QIAGEN Inc. Valencia, CA). A two-step
nested RT-PCR was carried out on all initial serum samples
according to Lanciotti et al. [19]. Negative and positive controls
were included in all steps. A purified and quantified dengue virus
control was added to the PCR test to confirm the limit of detection
of each assay of 10 genomic copies.
Serology
IgM ELISA. A total of 322 serum samples were used for IgM
and IgG antibody detection. An anti-dengue, IgM-capture ELISA
based on the viral envelop protein (Bio-Manguinhos, Fundac¸a˜o
Oswaldo Cruz, Brazil) was performed according to the
manufacturer’s instructions. Results were interpreted as negative
or positive according to the assay manual.
IgG ELISA. An anti-dengue, IgG-capture ELISA (PanBio,
Pty., Ltd., Brisbane, Australia) was performed according to the
recommended guidelines. In brief, 100 ml/well of patient or
control sera, diluted 1:100 in the reagent provided, was added to
the assay plate, containing a combination of the envelope antigens
(DENV-1, 2, 3 and 4) attached to its surface. After incubation, the
residual serum was removed by washing, and 100 ml/well of
peroxidase-conjugated anti-human IgG was added. After
incubation and washing steps, 100 ml/well of the substrate
system (tetramethylbenzidine / hydrogen peroxidase) was added.
The reaction was stopped by the addition of 100 m/well of 1 M
phosphoric acid and the absorbance was read at 450 nm. The
results were calculated and interpreted according to
manufacturer’s instructions. Anti-dengue IgG PanBio units were
calculated by dividing the sample absorbance by the cut-off value
and then multiplying this value by 10 (IgG Reference Unit).
Results of PanBio Units were interpreted as follow: .11, positive;
,9, negative; and 9–11, equivocal. The cross-reactivity of the
IgG-ELISA PanBio was investigated in dengue-IgG negative
samples from 32 yellow fever vaccinees. There was no detectable
dengue seroconvertion due to 17DD vaccination among these
individuals, indicating very low cross-reactivity of the PanBio kit
with yellow fever vaccinees (Table S1). However, six of the 32
dengue-negative IgG seroconverted 45 to 90 days later as a result
of natural dengue infection, as determined by the presence of
dengue specific IgM.
In house IgG-ELISA (‘‘Rio’’ method). The in-house IgG-
ELISA was conducted at the Flavivirus Laboratory of the Instituto
Oswaldo Cruz (IOC), Fiocruz (Rio de Janeiro, Brazil); the protocol
used for the characterization of dengue immune response was
previously described by Miagostovich et al [13]. Briefly, plates (96-
well (8612) microtiter plate, Immulon II, Dynatech, Inc.,
McLean, VA) were covered with 100 ml/well of hyper immune
ascitic fluid (a mixture of anti-DENV-1, 2, 3 and 4 in equal parts)
diluted in 0.1 M sodium carbonate buffer, pH 9.6, and were
incubated overnight at 4uC. After washing, wells were blocked by
filling with standard diluents (PBS pH 7.4/0,05% Tween/3%
normal goat serum) and incubated for 1 h at 37uC. Seventy five
microliters of 32 hemagglutinating units of purified virus antigen
mix (DENV-1, 2, 3 and 4), diluted in standard diluents, was
applied to each well and plates were incubated for 1 h at 37uC.
After being washed three times in PBS, 100 ml of serum diluted
1:40 in PBS/Tween/3% non-fat dry milk (NFDM diluents) was
added to the first well in each column and 75 ml of the same
diluents was added to the remaining wells. Four-fold dilutions were
carried out to the eighth well in each column by transferring and
mixing 25 ml. Plates were incubated for 1 h at 37uC, washed
NFDM diluents was added. After incubating for 1 h at room
temperature, plates were washed six times and 100 ml of substrate
(ABTS) were added to each well. Plates were incubated at room
temperature for 30 minutes, for color development, and the
absorbance was read at 450 nm. Each plate contained a negative
serum control, and the absorbance of each dilution was subtracted
from the corresponding dilution of each test sample. According to
this IgG-ELISA criteria, the immune response is defined as
primary when acute-phase serum samples obtained before day 5 of
illness have IgG antibody titers ,1:160 and convalescent-phase
sera have titers #1: 40,960. Infections are defined as secondary
when IgG titers are $1:160 in the acute-phase serum and
$1:163,840 in convalescent-phase samples. The correlation of
titers and serologic interpretations between IgG-capture ELISA
and the hemagglutination inhibition assay (HI) were applied to
validate the in-house IgG-capture ELISA.
Hemagglutination Inhibition assay (‘‘HI’’ method). The
HI test was performed aiming to classify the patient’s immune
response and compare the results to the other two methods above.
The HI assay [10] modified to a microtiter plate format was
performed on paired serum samples from all the 50 cases used as
the independent test set. Antigens of DENV-1, -2, -3 and Yellow
Fever, provided by the Evandro Chagas Institute (Bele´m-Para´),
Brazil, were used. The dengue immune response was classified
according to WHO criteria [7]: cases with no HI antibodies
(,1:20) in acute phase serum collected before the fourth day of
disease and convalescent phase serum samples with an HI titer
,1:1280 were classified as primary infection. Infections were
classified as secondary in patients with HI antibody titers of 1:20 or
greater in the acute phase serum and a convalescent HI antibody
titer greater than or equal to 1:2560 [7]. A summary of the results
of all the tests performed on the independent set of standard
samples is shown in Table 2.
Statistical analysis. Data analysis and plotting were carried
out using the open-source R statistical package, Version 2.2.1 [20].
Multivariate regression analysis was performed by fitting a linear
model using the R function lm, and p-values for trends, intercepts
and interaction were obtained by the lm function from t-tests for
the significance of the corresponding coefficients in the model.
The F-test for the difference in variances was performed by the R
function var.test. Linear discriminant analysis (LDA) was used
to design a 2-D classifier, using as variables both the IgG unit level
and the day of infection. LDA was coded in R directly from its
definition in terms of group means and covariance matrices; e.g.,
see [21]. The bolstering resubstitution error estimation method
used to assess the accuracy of the classifiers is based on the work
described in [22]. Basically, it decreases the optimistic bias of the
simple resubstitution error estimate (agreement-checking on the
training data) by means of suitable bolstering probability density
kernels placed at each training data point, producing a nearly-
unbiased and low-variance estimator. The statistical analyses of
test-set accuracy were performed in a blinded fashion, and the
estimates were based on counting the number of correctly
classified test samples and dividing by the total number of test
samples. Confidence intervals for the test-set estimates were
obtained from the binomial distribution, using the R function
binom.test. The R code for LDA and bolstered resubstitution
error estimation is provided as supplementary material
(Statistical package S1) and is available for downloaded at this
journal site.
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Table 2. Characterization of the ‘‘Standard Test Set’’ samples used for test validation.
Patient and
sample Nu Nu days Diagnostic Tests HI test
In house IgG ELISA
(‘‘Rio’’ method)
Classification/ Type
of Infection
IgM RT- PCR IgG RU DENV1 DENV2 DENV3 YFV
262 S1 2 POS NEG 31 1:160 1:160 1:320 1:160 1:2560 S
262 S4 15 POS 32 $1:2560 $1:2560 $1:2560 $1:2560 1:40960
301 S1 4 POS NEG 25 $1:2560 1:640 1:80 1:1280 1:2560 S
301 S3 17 POS 29 $1:2560 $1:2560 1:640 $1:2560 1:10240
329 S1 2 POS NEG 38 $1:2560 $1:2560 1:640 $1:2560 1:10240 S
329 S4 11 POS 40 $1:2560 $1:2560 $1:2560 $1:2560 1:163840
331 S1 4 POS D3 22 1:1280 1:640 1:80 1:1280 1:2560 S
331 S4 14 POS 44 $1:2560 $1:2560 1:1280 $1:2560 1:163840
332 S1 4 POS NEG 38 $1:2560 1:640 1:80 1:640 1:10240 S
332 S4 11 POS 38 $1:2560 $1:2560 $1:2560 $1:2560 1:163840
339 S1 6 POS D3 2 ,1:20 ,1:20 1:40 ,1:20 1:40 P
339 S3 14 POS 27 1:40 1:40 1:320 1:20 1:10240
348 S1 5 NEG NEG 29 1:1280 1:640 1:160 1:640 1:10240 S
348 S3 23 POS 37 $1:2560 $1:2560 $1:2560 $1:2560 1:40960
355 S1 4 NEG D3 2 ,1:20 ,1:20 ,1:20 ,1:20 ,1:40 P
355 S4 15 POS 19 1:80 1:40 1:320 ,1:20 1:2560
358 S1 5 POS D3 3 ,1:20 ,1:20 1:40 ,1:20 1:160 P
358 S3 11 POS 25 1:20 1:40 1:160 1:20 1:2560
361 S1 4 NEG D3 33 1:1280 1:640 1:40 1:80 1:10240 S
361 S4 17 POS 40 $1:2560 $1:2560 $1:2560 $1:2560 1:163840
370 S1 7 POS NEG 1 ,1:20 ,1:20 1:80 1:20 ,1:40 P
370 S3 12 POS 24 1:80 1:80 1:640 1:80 1:640
372 S1 3 NEG D3 1 ,1:20 ,1:20 ,1:20 ,1:20 ,1:40 P
372 S5 30 POS 30 1:80 1:40 1:640 1:40 1:160
382 S1 5 POS D3 27 $1:2560 1:640 1:160 1:640 1:10240 S
382 S4 12 POS 41 $1:2560 $1:2560 $1:2560 $1:2560 1:163840
400 S1 5 NEG D3 1 ,1:20 ,1:20 ,1:20 ,1:20 ,1:40* P
400 S3 15 POS 33 1:80 1:80 1:640 1:80 ,1:40
403 S1 7 NEG D3 46 1:40 1:20 ,1:20 1:40 1:10240 S
403 S3 13 NEG 39 $1:2560 $1:2560 1:1280 1:1280 1:163840
406 S1 6 NEG D3 2 ,1:20 ,1:20 ,1:20 ,1:20 ,1:40 P
406 S3 28 POS 20 1:80 1:80 1:640 1:80 1:10240
418 S1 4 NEG D3 14 1:40 1:20 ,1:20 1:40 1:160 S
418 S4 11 POS 18 $1:2560 $1:2560 1:1280 $1:2560 1:163840
419 S1 2 NEG D3 20 1:320 1:160 1:40 1:40 1:640 S
419 S4 16 NEG 45 $1:2560 $1:2560 $1:2560 $1:2560 1:40960
420 S1 4 POS D3 20 $1:2560 1:640 1:80 1:160 1:2560 S
420 S4 15 POS 22 $1:2560 $1:2560 $1:2560 $1:2560 1:163840
428 S1 3 NEG D3 18 1:1280 1:1280 1:40 1:80 1:2560 S
428 S4 15 NEG 54 $1:2560 $1:2560 $1:2560 $1:2560 1:163840
434 S1 5 NEG D3 44 1:1280 1:640 1:20 1:80 1:640 S
434 S4 13 POS 44 $1:2560 $1:2560 1:1280 1:640 1:163840
435 S1 5 NEG D3 45 $1:2560 1:640 1:20 1:40 1:2560 S
435 S3 32 NEG 59 $1:2560 $1:2560 1:1280 1:1280 1:163840
436 S1 5 NEG D3 48 $1:2560 $1:2560 1:320 1:40 1:2560 S
436 S3 34 NEG 51 $1:2560 $1:2560 $1:2560 1:320 1:163840
463 S1 4 NEG D3 45 $1:2560 $1:2560 1:160 1:40 1:10240 S
463 S4 16 NEG 55 $1:2560 $1:2560 $1:2560 $1:2560 1:163840
465 S1 5 NEG D3 16 1:40 1:160 ,1:20 1:20 1:40 S
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Patient and
sample Nu Nu days Diagnostic Tests HI test
In house IgG ELISA
(‘‘Rio’’ method)
Classification/ Type
of Infection
IgM RT- PCR IgG RU DENV1 DENV2 DENV3 YFV
465 S4 14 POS 42 $1:2560 $1:2560 $1:2560 $1:2560 1:163840
469 S1 4 NEG D3 43 1:1280 1:1280 1:160 1:320 1:10240 S
469 S4 17 POS 45 $1:2560 $1:2560 $1:2560 1:1280 1:163840
481 S1 5 NEG D3 39 1:640 1:640 1:40 1:160 1:10240 S
481 S4 16 POS 39 $1:2560 $1:2560 1:1280 1:1280 1:163840
483 S1 7 NEG D3 4 ,1:20 ,1:20 ,1:20 ,1:20 1:160 P
483 S3 18 POS 31 1:40 1:40 1:160 1:40 1:2560
486 S1 7 NEG D3 2 ,1:20 ,1:20 ,1:20 ,1:20 ,1:40 P
486 S3 21 POS 29 1:40 1:20 1:160 1:40 1:2560
496 S1 5 NEG D3 6 ,1:20 ,1:20 ,1:20 ,1:20 1:160 P
496 S4 13 POS 24 1:40 1:40 1:160 1:40 1:2560
497 S1 5 NEG D3 38 1:640 1:640 1:80 1:160 1:10240 S
497 S4 12 NEG 40 $1:2560 $1:2560 1:1280 $1:2560 1:163240
498 S1 8 POS D3 7 ,1:20 ,1:20 1:40 ,1:20 ,1:40 P
498 S4 15 POS 27 1:80 1:40 1:320 1:20 1:2560
502 S1 4 NEG D3 33 1:640 1:640 1:20 1:80 1:640 S
502 S4 12 POS 38 $1:2560 $1:2560 $1:2560 $1:2560 1:163840
506 S1 2 NEG D3 32 1:640 1:640 1:40 1:160 1:10240 S
506 S4 14 POS 45 $1:2560 $1:2560 1:1280 $1:2560 1:163840
521 S1 6 POS NEG 3 ,1:20 ,1:20 1:40 ,1:20 ,1:40 P
521 S4 18 POS 34 1:80 1:8 1:640 1:40 1:10240
523 S1 3 NEG D3 17 $1:2560 $1:2560 1:320 1:640 1:640 S
523 S2 7 POS 32 $1:2560 $1:2560 $1:2560 $1:2560 1:163840
524 S1 4 NEG D3 1 ,1:20 ,1:20 ,1:20 ,1:20 1:160 P
524 S4 24 POS 32 1:160 1:160 1:640 1:160 1:10240
527 S1 2 NEG D3 7 ,1:20 ,1:20 ,1:20 ,1:20 1:160* P
527 S4 10 POS 37 1:160 1:320 1:640 1:160 1:655360
533 S1 3 NEG D3 1 ,1:20 ,1:20 ,1:20 1:20 ,1:40 P
533 S4 10 POS 13 1:40 1:40 1:320 1:640 1:2560
537 S1 5 NEG NEG 42 $1:2560 $1:2560 $1:2560 1:1280 1:10240 S
537 S4 12 POS 38 $1:2560 $1:2560 $1:2560 $1:2560 1:163840
545 S1 5 NEG NEG 1 ,1:20 ,1:20 ,1:20 ,1:20 1:160 P
545 S4 13 POS 25 1:160 1:320 1:640 1:640 1:2660
546 S1 11 POS NEG 9 ,1:20 1:20 1:80 ,1:20 1:640 P
546 S3 33 POS 33 1:40 1:80 1:620 1:40 1:2560
547 S1 11 NEG NEG 1 ,1:20 ,1:20 ,1:20 ,1:20 1:640 P
547 S4 33 POS 20 1:80 1:40 1:640 1:80 1:2560
548 S1 4 NEG NEG 37 $1:2560 $1:2560 1:320 1:1280 1:10240 S
548 S2 9 POS 42 $1:2560 $1:2560 $1:2560 $1:2560 1:163840
553 S1 8 POS NEG 9 ,1:20 ,1:20 1:80 ,1:20 ,1:40 P
553 S4 15 POS 26 1:80 1:40 1:640 1:40 1:2560
554 S1 4 NEG NEG 2 ,1:20 ,1:20 ,1:20 ,1:20 1:160 P
554 S4 18 POS 16 1:160 1:80 1:320 1:80 1:10240
556 S1 4 NEG NEG 1 ,1:20 ,1:20 ,1:20 ,1:20 1:160 P
556 S4 13 POS 25 1:40 1:40 1:320 1:40 1:10240
559 S1 3 NEG D3 2 ,1:20 ,1:20 ,1:20 ,1:20 1:160 P
559 S4 11 POS 26 1:40 1:80 1:320 1:80 1:40960
564 S1 3 NEG NEG 4 ,1:20 ,1:20 ,1:20 ,1:20 1:640 P
564 S4 11 POS 21 1:40 1:80 1:320 1:40 1:10240
Table 2. Cont.
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Results
Samples from 109 well-defined dengue infection cases, com-
prising 54 male and 55 female volunteers, were used in this work
as reference samples. Summary of the demographic characteristics
of these patients is presented in the Table 1. Samples from 59
patients were selected as the training set; of these, 33 presented
primary infection, and 26 presented secondary infection, accord-
ing to the ‘‘Recife’’ classification method, as defined in the
methods section. A separate independent test set was established
using data from the remaining additional 50 patients; of these, 24
corresponded to primary and 26 to secondary infection, again
according to the Recife method. A schematic flow chart outlining
the data processing steps is depicted in Figure 1.
The 59 patients of the training set provided two to five blood
samples collected on different days. After about day 20, it is not
possible to distinguish the IgG responses from the primary and
secondary infection samples. Therefore, we limited our analysis to
samples taken ,=20 days from the start of symptoms. For the
training set, this resulted in 93 primary infection samples and 67
secondary infection samples, for a total of 160 training samples
(Figure 1).
Figure 2 shows a plot of IgG unit values versus number of days
of symptoms for the 160 samples in the training data set. A
multivariate linear model was fitted to this data, with IgG units as
the dependent variable being regressed on days of fever and
infection type (primary/secondary). The fitted line for the primary
infection group (red circles) gave IgG=26.865+2.1266day,
Patient and
sample Nu Nu days Diagnostic Tests HI test
In house IgG ELISA
(‘‘Rio’’ method)
Classification/ Type
of Infection
IgM RT- PCR IgG RU DENV1 DENV2 DENV3 YFV
576 S1 5 NEG D3 7 ,1:20 ,1:20 ,1:20 ,1:20 1:160 P
576 S2 7 POS 34 1:40 1:40 1:160 1:40 1:10240
Nu days, number of days from the start of the symptoms; P, primary infection; S, secondary infection; NEG, negative; POS, positive; YFV, yellow fever virus; D3, DENV-3;
RU, reference unit.
*discordant result.
doi:10.1371/journal.pone.0004945.t002
Table 2. Cont.
Figure 1. Data flow for standard samples from the cohort of dengue fever patients. Two to five blood samples were obtained from the
patients on different days; these samples were pooled, resulting in 119 primary infection samples and 81 secondary infection samples, for a total of
200 samples. The effective training data set consisted of all available training samples from day 20 or earlier (93 primary and 67 secondary samples,
for a total of 160). After design of the 2-D classifier, its accuracy was assessed both by training set bolstered error estimates and independent test-set
error estimates. For the test set, the available samples were pooled, and those obtained after 20 days from the self-reported onset of symptoms were
eliminated from consideration. The resulting test set had 51 primary and 61 secondary samples, for a total of 112 samples. The test set was also used
to assess the accuracy of a diagnostic classifier that used all available samples for each patient.
doi:10.1371/journal.pone.0004945.g001
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whereas the one for the secondary infection group (blue triangles)
gave IgG=24.327+0.6746day. The regression lines are depicted
as dashed lines in Figure 2, superimposed on the training data.
The primary infection samples began with low IgG levels that
quickly rose with time, whereas the secondary infection samples
began with a nonzero basal value (reflecting immunological
memory) and raised little over time. The slopes (dependence on
day of infection) and intercepts were highly significant, for both
primary and secondary infection groups (p,0.0005 in all cases).
There were very few outliers. An F-test to compare the variances in
the two groups does not reject the hypothesis that they are identical
therefore the multivariate model allows us to test jointly the two lines.
We find that the difference between the intercepts is highly
significant (p,10215), indicating a difference in initial immune
response that reflects immunological memory in the case of the
dengue-specific IgG. In addition, there is significant interaction
between infection type and days of symptoms (p,1027), that is, the
lines are not parallel, and the trends within each group are
significantly different, suggesting that it may be possible to define
acute dengue infections on the basis of the rise in IgG level alone;
however, this is not the goal of this study. The two regression lines
converge near the 20-day limit, which is another indication that the
groups cannot be reliably discriminated beyond this number of days.
Linear Discriminant Analysis (LDA) was performed to obtain a
linear classifier based on these data (the outlier samples were not
excluded). The equation for the LDA line is y = 7.494+1.6236. The
LDA classifier is depicted as a solid line in Figure 2.
Table 3 displays some of the threshold values calculated using
the designed classifier equation (y = 7.494+1.6236) for the IgG
units used to classify samples as indicating primary infection
(below the threshold) or secondary infection (above the threshold),
as a function of sample collection day. As expected, the threshold
values increase over time. Sensitivity and specificity for this
classifier were estimated via two methods. First, we used the
training data itself to derive bolstered resubstitution error estimates
(see Methods section). The estimated sensitivity and specificity
found were 91.64% and 92.46%, respectively. The classifier
recommended by the manufacturer corresponds to a horizontal
line at IgG unit threshold = 40. This did not perform satisfactorily
at all on our data, as this classifier is completely non-specific (this
can be seen in Figure 2, which shows that almost all of the
secondary infection IgG responses are below 40, not above).
Decreasing the IgG unit level from the recommended value of 40
to the optimal one-dimensional classifier improves accuracy, but
not to an acceptable level (data not shown). This underscores the
need to include the stage (day) of disease as a classification
variable, as in the proposed LDA classifier, to account for rising
levels of IgG response. Secondly, the designed LDA classifier was
tested on an independent set of samples, obtained from 50
additional patients, as described earlier (Figure 1). This typically
results in a more accurate error estimator than the one using the
training samples, provided the number of test samples is large. As
before, we pooled all quantified sample data and ignored those
that had been obtained more than 20 days after the onset of
symptoms, resulting in 51 primary and 61 secondary infection
samples, for a total of 112 test samples. This test set is large enough
to allow accurate estimates of classification accuracy. Figure 3
displays the data for these samples, overlapped on the proposed
classifier for inspection.
Based on this independent test set of 112 samples, the estimated
sensitivity and specificity of the proposed classifier, using as
groundtruth the results of the Recife method, were 92.16% (95%
Figure 2. Training data, with primary and secondary infection
classification according to the CPqAM criteria, with regression
lines (dashed lines) and LDA classifier (solid line) superim-
posed. The regression line for the primary infection group corresponds
to the equation IgG=26.865+2.1266day, whereas the one for the
secondary infection corresponds to IgG= 24.327+0.6746day. The slopes
(dependence on day of infection) and intercepts were highly significant,
for both primary and secondary infection groups (p,0.0005 in all
cases). The difference between the intercepts is also highly significant
(p,10-15), indicating a difference in initial immune response that
reflects immunological memory in the case of the dengue-specific IgG.
In addition, there is significant interaction between infection type and
days of fever (p,10-7), that is, the lines are not parallel, and the trends
within each group are significantly different, suggesting that it may be
possible to define acute dengue infections on the basis of the rise in
IgG level alone. The two regression lines converge near the 20-day limit,
indicating that the groups cannot be reliably discriminated beyond this
number of days. The equation for the LDA line is y = 7.494+1.6236x. The
LDA classifier is depicted as a solid line in Figure 2.
doi:10.1371/journal.pone.0004945.g002
Table 3. Threshold values for the IgG units reference values
used to classify samples into primary infection (below the
threshold) or secondary infection (above the threshold), as a
function of sample day, according to the designed LDA
classifier.
Days of symptoms onset IgG Unit Threshold
0 7.5
2 10.7
4 14.0
6 17.2
8 20.5
10 23.7
12 27.0
14 30.2
16 33.5
18 36.7
20 40.0
doi:10.1371/journal.pone.0004945.t003
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CI= 81.12 to 97.82) and 95.08% (95% CI= 86.29 to 98.97),
respectively. These accuracy estimates are not appreciably
different from those obtained previously by bolstered resubstitu-
tion. The proposed classifier was able to correctly predict 47 of the
51 primary samples and 58 of the 61 secondary samples. We also
used the independent test data to break down the estimates of
accuracy according to various ranges of days of infection (Table 4).
The results were consistent with the expectation that classification
between primary and secondary infection would be easier early in
the infection than at later times. The proposed classifier performed
perfectly with samples taken on day 4 or earlier, but its sensitivity
and sensibility decreased with time.
As a final test, the serum samples from the independent test set
were also classified according to the hemagglutination inhibition
(‘‘HI’’) method and to an in-house IgG-captrue ELISA (‘‘Rio’’)
method [13], as defined in the Methods section, aiming to
characterize the serological immune response and classify the
infections as primary or secondary. From the panel of 50-paired
sera, 24 cases were characterized as primary cases and 26 as
secondary ones by the HI method (Table 2). Complete (100%)
agreement was observed between the proposed classifier and the
HI method (WHO criteria) in the classification of primary and
secondary dengue infections. The Rio method identified 26
secondary infections, 22 primary infections and 2 inconclusive
cases. Using these results as the groundtruth, we obtained an
overall accuracy of 96% (48/50) for the proposed classifier. Using
the HI method as groundtruth, the Rio method was more sensitive
in confirming secondary cases (100%, 26/26) than primary ones
(92%, 22/24). There was one instance where both the Recife and
HI method called one patient as primary infection, whereas the
call according to the Rio method was secondary infection.
Discussion
In this manuscript, we describe a process for designing and
validating a classification method to discriminate between primary
and secondary dengue infections based on IgG antibody levels and
the number of days of symptoms, and we demonstrate that a 2-D
classifier designed using this approach is very reliable. We make
available software that enables the user to insert their IgG data for
the training and test data sets from their standard samples and
obtain a validated 2-D classifier, which in our study generates
classifications identical to the ones made by the HI assay.
Although secondary infection with dengue virus is the most
widely accepted risk factor for the development of dengue
hemorrhagic fever, there is no simple, rapid, and reliable method
that can routinely be used to discriminate between primary and
secondary infections in the early days of an infection. Distinguish-
ing between primary and secondary infections can be of great
importance, particularly in endemic areas in which the dengue
virus has recently arrived and primary infections are also frequent.
Moreover, laboratory confirmation of acute dengue infection can
sometimes be difficult, depending on the how many days the
person has been sick and what diagnostic tests are available. It is
important to note that the proposed 2-D classifier is not intended
to determine the presence of an acute dengue infection, but to
classify an acute infection as primary or secondary. In our
experience, the ideal combination of tests to detect an acute
infection in the first 5 days of symptoms is the use of RT-PCR
associated with IgG serology to classify infection history, and from
the sixth day of symptoms and after, the use of IgM and IgG
serology.
The most commonly used serological test is IgM-capture
ELISA. Nevertheless, this test is not sufficiently sensitive during
the first 3–5 days of symptoms. In primary cases, both IgM and
IgG antibody detection often will give negative results during this
period. Thus, in these early days of disease a diagnosis will only be
possible by RT-PCR, virus isolation and/or dengue NS1 antigen
detection by ELISA. It should be pointed out that in some
secondary dengue infections, specific IgM is often not detected at
all.
The hemagglutination inhibition assay has been the gold
standard for the serological diagnosis of dengue infection, as well
as to classify the patient’s dengue immune response [7]. However,
the most reliable way to define primary and secondary dengue
infection is based on a combination of multiple laboratory tests
(virus isolation and/or detection of virus RNA by PCR, IgM and
IgG antibody detection) performed on blood specimens collected
at two time points, at least. A primary dengue infection is defined
Table 4. Accuracy of the proposed LDA classifier according to
ranges of days of symptoms, based on the independent test
set, with 95% confidence interval limits.
Days of Symptoms Sensitivity Specificity
1–4 100.00 (66.37–100.00) 100.00 (80.49–100.00)
5–8 94.44 (72.71–99.86) 100.00 (78.20–100.00)
9–12 84.62 (54.55–98.08) 95.24 (76.18–99.88)
13–20 90.91 (58.72–99.77) 75.00 (34.91–96.81)
#20 92.16 (81.12–97.82) 95.08 (86.29–98.97)
doi:10.1371/journal.pone.0004945.t004
Figure 3. Independent test data, with primary and secondary
infection classification according to the CPqAM criteria, with a
solid line representing the previously designed classifier, for
inspection. Test data were obtained from 50 additional patients in the
cohort. As with the training data, all quantified samples were pooled
and those that had been obtained more than 20 days after the onset of
symptoms were ignored, resulting in 51 primary and 61 secondary
infection samples, according to the CPqAM criteria, for a total of 112
test samples.
doi:10.1371/journal.pone.0004945.g003
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as the absence of specific anti-dengue IgG antibodies in the first
serum samples during the acute phase, with anti-dengue IgM,
virus isolation and/or virus RNA being present, and dengue virus
IgG being detected in a later sample. In contrast, secondary
dengue infection is defined by the presence of specific anti-dengue
IgG and the absence of anti-dengue IgM in the first sample,
together with a positive RT-PCR and/or virus isolation, followed
by the presence of anti-dengue IgM in a later sample. Defining
primary and secondary dengue infections by means of these
rigorous criteria is very expensive, and most clinical laboratories in
dengue-endemic countries cannot realistically perform all these
assays on all of their samples. Moreover, even when all the assays
are available, because of the dates of the blood collections and the
immunological windows, it is not always possible to unambigu-
ously define primary versus secondary dengue infections. The
main caveat is that depending on how long the patient is sick
before the first sample is collected, it may be possible to detect
anti-dengue specific IgG at the time of the first medical visit in a
primary dengue infection. Furthermore, classification of primary
versus secondary dengue immune responses exclusively on the
basis of the HI test, following the WHO criteria [7] it is not always
reliable and can be misleading [6]. In this case, diagnosis is based
on the antibody titers of paired serum samples, and cross-reactivity
among flaviviruses is common and can lead to false results. In
addition, during acute secondary dengue infection, pre-existing
serotype-specific antibodies are boosted [4], and if the number of
days since the onset of symptoms is not taken into account, the HI
test can result in misleading classification. In contrast, in a separate
study we have found no evidence of cross-reactivity of the PanBio
dengue IgG ELISA with sera from with Yellow Fever 17DD
vaccinated volunteers (Table S1). Six of the 32 Yellow fever
vaccinees presented dengue-specific IgG 45 to 90 days after the
vaccination, however it was later confirmed that those individuals
had natural dengue infection. Cross-reactivity among flavivirus
diagnostic kits are common and it is important to select a dengue-
IgG kit with minimum cross-reactivity with other local flavivirus,
however differentiating cross-reactivity against natural infection
may not be an easy task in endemic areas. If possible, it is
important actually verify with standard samples collected locally.
Thus, a simple alternative laboratory method for the classifica-
tion of primary and secondary dengue antibody responses is highly
desirable. Matheus et al. [12] developed an IgG avidity test to
discriminate between primary and secondary dengue virus
infection using a single acute-phase serum sample and claimed
good sensitivity and specificity. However, the real performance of
this method still need to be evaluated in independent reference
standard samples from patients for whom the classification of
serological response was based on criteria other than only the HI
test. The results from our dengue cohort clearly support the
contention that to correctly delineate primary and secondary
responses, it is strictly necessary to combine several assays, such as
IgM and IgG levels, virus isolation and/or viral RNA detection.
For example, an absence of IgM in some secondary cases, even in
later samples, was seen in several of our dengue cohort patients,
and this phenomenon has also been observed by others [23].
Dengue infections could be characterized as primary or secondary
by determining the ratio of units of dengue IgM to IgG antibody
[23]. However there are many cases where IgM is undetectable or
not yet present and this criterion could not be applied. It would be
necessary another test to confirm the acute dengue infection, for
example, a positive RT-PCR, which is the most sensitive method
to confirm dengue infection at the early days of the disease.
Because IgM and IgG dengue ELISAs kits are commercially
available at relatively low cost, dengue fever diagnosis is now being
done in many laboratories worldwide. In this study we took
advantage of the existence of a good commercial IgG-ELISA kit to
develop a 2-D classifier, using IgG levels and self-reported days of
symptoms from a cohort of 109 patients with well-characterized
primary or secondary dengue infections. This approach would
allow to define, according to how many days of symptoms, what
levels of anti-dengue IgG would be compatible with primary or
secondary infections.
We have found, by using multiple accuracy estimation methods,
that the sensitivity and specificity of the designed 2-D LDA
classifier are vastly superior to the most commonly used stage-
independent 1-D classifiers (data not shown). For individual
sample classification, estimates of sensitivity and specificity of the
2-D classifier were in the range of 90–95%. For patient
classification using a majority-voting rule, independent test-set
estimates of both sensitivity and specificity were 100%.
The 2-D LDA classifier was tested in an independent set of 50
patients and the results compared with two other methods, the HI
assay, according to WHO guidelines [7] and an in-house made
ELISA. There was a total 100% agreement between the HI results
and our 2-D LDA classifier. When those results were compared to
the in-house IgG-ELISA (‘‘Rio’’ method) described by Miagosto-
vich et al. [13], the overall sensitivity was 96% (48/50). As
expected, the Rio method was more sensitive in confirming
secondary cases (100%, 26/26) than primary ones (92%, 22/24).
In primary infections, the Rio method is generally negative in the
first week after the onset of the disease and individual variation
may occur. Therefore, for a definitive and reliable result using the
Rio method, it is important in some cases to also use a second
sample from the convalescence phase. However when used
samples from the acute and convalescent phase the results are
clear, because the Rio titers in acute samples are low (up to day 5
after the onset of the disease) and very high in convalescent sera
from secondary dengue cases as previously described by
Miagostovich et al. [13]. These two independent tests results
corroborated our immune response classification results (Table 2).
The classifier developed in this study is currently being used, in
daily practice, in our laboratory and has shown excellent
performance on independently validated data that is compatible
with the results presented here. Indeed, in our on going dengue
study the most reliable and cost efficient combination of diagnostic
exam is the detection of anti-dengue IgM, IgG and RT-PCR.
With this combination of tests we can determine in 100% of the
cases the presence of acute dengue infection, the viral serotype and
with the use of the 2-D classifier, the patient serological history
within 24 hours of the first blood sample collected.
It is noteworthy that very few primary and secondary standard
samples were dispersed among samples of the other type (Figures 2
and 3), suggesting also that patient-reported number of days of
dengue symptoms, although a subjective measure, is considerably
more accurate than often acknowledged. We would also like to
point out that the methodology described here can be employed to
design classifiers based on results from kits other than the PanBio
kit or in-house assays such as the one in the Rio method, as long as
a good set of standard primary and secondary reference samples is
available.
According to the manufacturer of the PanBio kit, and as found
by Vaughn [15], an IgG result of 40 PanBio units correlates with
an HI titer of $1:1280, the cut-off used to distinguish between
primary and secondary dengue infection based on WHO criteria
[7]. Thus, using this criteria, a result of .40 IgG units can be used
to identify a secondary infection and IgG units of .11–40 to
detect a primary infection. However, we have shown that these
suggested values do not provide reliable classification results in
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patients from our cohort, nor does any stage independent 1-D
classifier that does not take in consideration when a sample was
collected in relation to the onset of symptoms.
In conclusion, laboratories in endemic areas interested in
distinguishing acute primary dengue infections from acute
secondary infections can use the methodology we have described
here. These laboratories can collect and characterize a set of
reference samples from acutely ill patients in their region, and if
necessary some of the characterization assays may be carried by
another laboratory; they can then design a reliable 2-dimensional
classifier based only on the IgG levels quantified by a clinical assay
kit and the number of days of symptoms reported by the patient.
In the supplemental material we provide for download R software
for the calculation of the LDA classifier, as well as the bolstered
resubstitution error estimator, and instructions that other labora-
tories can use to design their classifiers (Statistical Package S2). We
ask the users of this classifier to share the classification data,
classifier performance and standard samples with other investiga-
tors using the PLoS One post-publication and communication
tools. By applying this classifier in samples from other cohorts and
sharing the results we can further strengthen the validation and
define the value of this method. In addition, we will offer and make
available in our laboratory web site an interface to a set of dengue
diagnostic tools and database (http://augustlab.bs.jhmi.edu/
index.html). The use of this approach can allow clinicians to
more quickly and reliably identify whether their patients are
experiencing a primary or secondary dengue infection, which
allows the assessment of risk of developing DHF in order to decide
what is the most appropriate care and also reduce cost by reducing
hospitalizations worldwide.
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